Napo pharmaceuticals, a jaguar health company, announces activation by fda of investigational new drug (ind) application for crofelemer for treatment of microvillus inclusion disease

Mvid is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea san francisco, ca / accesswire / august 8, 2023 / napo pharmaceuticals inc. (napo), a jaguar health, inc. (nasdaq:jagx) company, today announced the activation by the u.s. food and drug administration (fda) of the investigational new drug (ind) application for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (mvid), an ultra-rare congenital diarrheal disorder (cdd). "we were very pleased to hear that the fda has communicated that we may proceed with the proposed phase 2 clinical trial for crofelemer for treatment of mvid in pediatric patients with a novel formulation of crofelemer," said lisa conte, napo and jaguar's president and ceo.
JAGX Ratings Summary
JAGX Quant Ranking